GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCCP.PFD) » Definitions » Total Equity

CYCCP.PFD (Cyclacel Pharmaceuticals) Total Equity : $-0.97 Mil (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Cyclacel Pharmaceuticals Total Equity?

Cyclacel Pharmaceuticals's total equity for the quarter that ended in Sep. 2024 was $-0.97 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cyclacel Pharmaceuticals Total Equity Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Total Equity Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.70 33.26 37.69 20.43 0.61

Cyclacel Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.30 0.61 -2.21 1.00 -0.97

Cyclacel Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cyclacel Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=8.805-8.198
=0.61

Cyclacel Pharmaceuticals's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=5.381-6.351
=-0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclacel Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCCP.PFD) » Definitions » Total Equity
Comparable Companies
MTEM QRON HALB DRMA ENTO GRTX SXTP BTAX SONN SLRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CYCC:USA UXI:Germany
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Website
https://cyclacel.com
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.